Scilex Holding Company
SCLXHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Scilex Holding Company (SCLX) is listed under Drug Manufacturers - General. Valued at $55.1M, SCLX is a micro-cap name in its sector. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Market Cap
$55.1M
Beta
1.73
P/E (TTM)
—
P/E (Fwd)
10.74
EPS (TTM)
$-41.95
EPS (Fwd)
$0.73
ROE
—
ROA
-92.8%
Cash
$3.4M
Total Debt
$106.4M
Free CF
$6.0M
52W Change
42.4%
Annual Financials
Cash vs Debt
Where SCLX stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, SCLX finished 55.01% above its 150-day moving average ($6.09) and 27.05% above its 200-day moving average ($7.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCLX overbought or oversold?
At the July 14, 2026 close, SCLX's RSI(14) was 79.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Scilex Holding Company carries $106.4M in total debt against $3.4M in cash reserves — debt is roughly 31.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $6.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Revenue has been uneven over recent years, ranging from $38.0M to $30.3M.
Scilex Holding Company's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing SCLX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.